- Previous Close
1,319.70 - Open
1,202.00 - Bid 1,274.30 x --
- Ask 1,283.35 x --
- Day's Range
1,187.10 - 1,290.00 - 52 Week Range
815.50 - 1,593.00 - Volume
2,731 - Avg. Volume
6,018 - Market Cap (intraday)
173.635B - Beta (5Y Monthly) 0.12
- PE Ratio (TTM)
52.80 - EPS (TTM)
24.15 - Earnings Date May 19, 2025 - May 23, 2025
- Forward Dividend & Yield 14.70 (1.11%)
- Ex-Dividend Date Feb 13, 2025
- 1y Target Est
1,509.22
Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India. The company offers various branded formulations in various therapeutic areas, such as antidiabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women's health, and vitamins/minerals/nutrients. It also provides patient care services, including ambulatory blood pressure measurement, ambulatory electrocardiogram measurement, continuous glucose monitoring system, sleep study, and ante-natal care solutions. It offers its products through wholesale drug distributors, and stockiest and retail pharmacies. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.
www.eris.co.in3,620
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: ERIS.BO
View MorePerformance Overview: ERIS.BO
Trailing total returns as of 4/7/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ERIS.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ERIS.BO
View MoreValuation Measures
Market Cap
179.69B
Enterprise Value
204.58B
Trailing P/E
54.58
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.60
Price/Book (mrq)
6.48
Enterprise Value/Revenue
7.51
Enterprise Value/EBITDA
21.79
Financial Highlights
Profitability and Income Statement
Profit Margin
12.09%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
27.24B
Net Income Avi to Common (ttm)
3.29B
Diluted EPS (ttm)
24.15
Balance Sheet and Cash Flow
Total Cash (mrq)
2.43B
Total Debt/Equity (mrq)
86.08%
Levered Free Cash Flow (ttm)
--